PROSCA BLADDR 2021 | PROOF 302: adjuvant infigratinib in FGFR3-mutant invasive UC
Petros Grivas
• 19 Oct 2021
Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, outlines the rationale and background of the ongoing PROOF 302 study (NCT04197986), a randomized, double-blind, placebo-controlled, Phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations. Dr Grivas follows by highlighting recent data evaluating adjuvant treatment approaches in this patient population. This interview took place at the PROSCA/BLADDR 2021 congress.
